ストックスクリーナーアプリを入手
52.45
1.34%
-0.71
前日終値:
$53.16
開ける：
$53.56
24時間の取引高:
927.11K
Relative Volume:
2.07
時価総額：
$2.52B
収益：
$307.03M
当期純損益:
$-99.81M
株価収益率:
-25.34
EPS:
-2.0695
ネットキャッシュフロー:
$-27.20M
1週間 パフォーマンス:
+4.82%
1か月 パフォーマンス:
+9.32%
6か月 パフォーマンス:
+27.18%
1年 パフォーマンス:
+85.40%
1日の値動き範囲:
$52.05
$54.23
1週間の範囲:
$49.48
$54.23
52週間の値動き範囲:
$23.14
$54.23
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
名前
Mirum Pharmaceuticals Inc
セクター
電話
650-667-4085
住所
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
MIRM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
52.45 | 2.52B | 307.03M | -99.81M | -27.20M | -2.0695 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-17 | 開始されました | Stifel | Buy |
| 2023-12-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-11-13 | 開始されました | Morgan Stanley | Overweight |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 再開されました | Evercore ISI | Outperform |
| 2023-09-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2021-09-20 | 開始されました | JP Morgan | Overweight |
| 2020-08-07 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-06-25 | 開始されました | Robert W. Baird | Outperform |
| 2019-08-12 | 開始されました | Citigroup | Buy |
| 2019-08-12 | 開始されました | Evercore ISI | Outperform |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | ROTH Capital | Buy |
| 2019-08-12 | 開始されました | Raymond James | Outperform |
すべてを表示
Mirum Pharmaceuticals Inc (MIRM) 最新ニュース
Mirum’s Ctexli wins FDA nod in cerebrotendinous xanthomatosis - BioWorld Online
US FDA approves Mirum Pharma's genetic disorder drug - Reuters
Mirum Pharmaceuticals' Lipid Storage Disease Treatment Gets FDA Approval -February 21, 2025 at 01:48 pm EST - Marketscreener.com
US FDA approves Mirum Pharma’s genetic disorder drug - KFGO
FDA Approves Mirum Pharmaceuticals Treatment for Lipid-Storage Disease -February 21, 2025 at 01:20 pm EST - Marketscreener.com
FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol - Benzinga
Mirum gains FDA approval of chenodiol for rare lipid storage disease - Seeking Alpha
FDA Approves Mirum Pharmaceuticals Treatment for Lipid-Storage Disease - MarketWatch
US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 12:07 pm EST - Marketscreener.com
US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 11:54 am EST - Marketscreener.com
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025 - BioSpace
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 20 - WICZ
Mirum Pharma's Critical Q4 Earnings Call: Will 2024 Results Signal Growth Momentum? - StockTitan
High Growth Tech Stocks in United States to Watch - Simply Wall St
Mirum Pharmaceuticals stock soars to all-time high of $53.52 - Investing.com India
Mirum Pharmaceuticals stock soars to all-time high of $53.52 By Investing.com - Investing.com Nigeria
How to Take Advantage of moves in (MIRM) - Stock Traders Daily
Mirum Pharmaceuticals (MIRM) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Mirum Pharmaceuticals stock soars to all-time high of $48.94 - MSN
Alagille Syndrome Market Expected to rise, 2034 | Mirum Pharmaceuticals, Albireo, expected to drive market - Barchart
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Mirum Pharma (MIRM) Unveils Strategic Talent Package: 74K Shares in Equity Grants - StockTitan
SG Americas Securities LLC Sells 13,575 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 1,064 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Hits New 52-Week HighHere's What Happened - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $126,673.94 in Stock - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 9,102 Shares - MarketBeat
(MIRM) Technical Pivots with Risk Controls - Stock Traders Daily
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Golden State Equity Partners Has $801,000 Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Genomenon and Mirum Pharmaceuticals Join Forces to Enhance CTX Disease Awareness and Diagnosis - PR Web
Mirum Pharmaceuticals president sells $126,680 in stock - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) shareholder returns have been solid, earning 192% in 5 years - Simply Wall St
Major Insider Stock Sales at Mirum Pharmaceuticals! - TipRanks
Mirum Pharmaceuticals president sells $126,680 in stock By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year HighShould You Buy? - MarketBeat
Mirum Pharmaceuticals stock soars to all-time high of $49.59 - MSN
First Week of MIRM March 21st Options Trading - Nasdaq
Mirum Pharmaceuticals stock soars to all-time high of $49.59 By Investing.com - Investing.com UK
Recent Price Trend in Mirum Pharmaceuticals (MIRM) is Your Friend, Here's Why - Yahoo Finance
Mirum Pharmaceuticals SVP sells shares worth $43,227 By Investing.com - Investing.com Australia
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 902 Shares of Stock - MarketBeat
Christopher Peetz Sells 6,837 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock - MarketBeat
Mirum Pharmaceuticals CEO sells shares worth $327,658 By Investing.com - Investing.com Australia
Mirum Pharmaceuticals Inc (MIRM) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):